Great insight into the clinical process of Alzheimers care. I have worked on Amyloid programs before (early stage pharma R&D), and was wondering if there are significant clinical differences between lecanemab and aducanumab that makes you think this approval will have a less problematic trajectory? From my perspective, they are both mAbs targeting the same thing, but the discussion around lecanemab is different than it was for aducanumab, but perhaps that was primarily due to the non-standard phase 3 process of adu.
wjs018
joined 1 year ago
2
Space travel can alter gene expression in white blood cells, weakening our immune system
(medicalxpress.com)
1
Space travel can alter gene expression in white blood cells, weakening our immune system
(medicalxpress.com)
1
Senators offer legislation to address drug shortages, supply chain problems
(www.fiercepharma.com)
I have my PhD in physics with a background in material science and primarily work in Pharma developing early stage biologics programs (antibodies, gene therapies, etc). That means basically any of the molecules I have worked on are maybe 5+ years away from reaching the market. I don't meet many other physicists in this field, instead it is primarily chemical engineers and biochemists. Even working in industry, I still have the chance to publish and attend conferences though.
As an anime-only I have absolutely loved this series. I managed to go in completely blind and have been blown away. I am fully prepared to binge the manga as soon as this season is over.